Approved for use through 07/31/2008. OMB 0851-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

e Panerwork Reduction Apt of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number

titute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of

Complete if Known **Application Number** 09/964.273 Filing Date September 26, 2001 First Named Inventor Sean Brynjelsen Art Unit 1615 **Examiner Name** P. A. Hawes Attomey Docket Number CPIFT-5776 (3360-0004)

Sheet **U. S. PATENT DOCUMENTS** Cite **Document Number Publication Date** Name of Patentee or Pages, Columns, Lines, Where Examiner Initials* MM-DD-YYYY Applicant of Cited Document Relevant Passages or Relevant Number-Kind Code^{2 (if known)} Figures Appear 1 4,606,670 08/18/1986 Frank et al. 2 02/23/1999 5,874,111 Maitra et al. 3 05/16/2000 6,063,138 Hanna et al. 4 6,207,178 04/10/2001 Westesen et al. 5 10/08/2002 6,462,093 Miyamoto et al. 6 6,616,869 09/09/2003 Mathiowitz et al. 7 2003/0211083 11/13/2003 Vogel et al. 8 Williams 2004/0022861 02/05/2004 9 2004/0022862 02/05/2004 Kipp et al. 10 2004/0043077 03/04/2004 Brown 11 2004/0256749 12/23/2004 Chaubal 12 2005/0013868 01/20/2005 Brynjelsen et al. 13 02/17/2005 2005/0037083 Brynjelsen et al.

	 -					
Examiner Signature	//	A	<i>- / I</i>	lles	Date Considered	11-21-2005

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08a (07-05) Approved for use through 07/31/2006. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE the Panerwork Reduction Apt of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

Application Number 09/964,273

Filing Date September 26, 2001

First Named Inventor Sean Brynjelsen

Art Unit 1615

Examiner Name P. A. Hawes

Attorney Docket Number CRIET-5776 (3360,0004)

Sheet 2 of 4 Attorney Docket Number CPIFT-5776 (3360-0004)

		·	FOREIGN P	ATENT DOCUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ "Number ⁴ "Kind Code ⁵ (if known)	Publication Date MM-DD- YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Appear, etc.	T ⁶
W	14	JP H2-30609	12/20/1990	Harmari Co. et al.		X
	15	Patent Abstract of JAPAN 02306902	12/20/1990	Harmari Sangyo		Γ
	16	WO 92/17214 A2	10/15/1992	Ranney		T
	17	WO 94/07999 A1	04/14/1994	Univ Brown Res Found		T
	18	WO 95/33488 A1	12/14/1995	Quadrant Holdings Cambridge Ltd		T
	19	WO 97/03651 A1	02/06/1997	Danbiosyst UK		T
	20	WO 97/41837 A2	11/13/1997	Alkermes Inc		Γ
T	21	WO 98/01162 A2	01/15/1998	Univ Johns Hopkins		T
T	22	WO 98/14170 A1	04/09/1998	Sloan Kettering Inst		T
	23	WO 98/24450 A1	06/11/1998	Nilsson		T
	24	WO 99/39700 A1	08/12/1999	Vectorpharma SPA		T
	25	WO 99/59550 A1	11/25/1999	Lipsome Co		T
	26	WO 00/06152 A1	02/10/2000	Novopharm Biotech Inc		T
	27	WO 01/21154 A2 WO 01/21154 A3	03/29/2001	RTP Pharma Inc		T
	28	WO 02/82074 A1	10/17/2002	Chiron Corp		Τ
	29	WO 03/45330 A2	06/05/2003	Onyuksel et al		T
Τ.	30	WO 03/45660 A1	0 6/05/2003	BTG Int Ltd		T
M	31	WO 04/103348 A2 WO 04/103348 A3	12/02/2004	Baxter International		
	0					Į
						‡
						+
						#
		<u> </u>	 			4
	L		<u> </u>	<u> </u>	A.	1

Examiner Signature AM

Date Considered

11-21-2005

EXAMINER: Idual if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WiPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 8 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE ne Paperwork Reduction Apt of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number.

tute for form 1449B/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

4

Application Number 09/964,273

Filing Date September 26, 2001

First Named Inventor Sean Brynjelsen

Art Unit 1615

Examiner Name P. A. Hawes

Attorney Docket Number CPIFT-5776 (3360-0004)

	_	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
pp	32	Kinman et al., "Lipid-Drug Association Enhanced IHV-1 Protease Inhibitor Indinavir Localization in Lymphoid Tissues and Viral Load Reduction: A Proof of Concept Study in HIV-2 ₂₈₇ -Infected Macaques", Journal of Acquired Immune Deficiency Syndrome, 34(4), pp. 387-397	
	33_	Limoges et al., poster presentation, 11th Conference on Retroviruses and Opportunistic Infections, February 8-11, 2004.	
	34	Moghimi et al., "Long-Circulating and Target-Specific Nanoparticles: Theory to Practice", Pharmacological Reviews, 53, pp. 283-318, 2001.	
	35_	Nesbit et al., "In Vitro and Animal Models of Human Immunodeficiency Virus Infection of the Central Nervous System", Clinical and Diagnostic Laboratory Immunology, 9(3), pp. 515-524, May 2002.	
	36	Nottet et al., "HIV-1 Entry into Brain: Mechanisms for the Infiltration of HIV-1 infected Macrophages Across the Blood-Brain Barrier", The Neurology of AIDS, p. 55, 1998.	
	37	Perno et al., "Relative Potency of Protease Inhibitors in Monocytes/Macrophages Acutely and Chronically Infected with Human Immunodeficiency Virus", The Journal of Infectious Diseases, 178, pp. 413-422, 1998.	
	38	Sawchuk et al., "Investigation of distribution, transport and uptake of an anti-HIV drugs to the central nervous system", Advanced Drug Delivery Reviews, 39, pp. 5-31, 1999.	
	39	Solas et al., "Discrepancies between Protease Inhibitor Concentrations and Viral Loan in Reservoirs and Sanctuary Sites in Human Immunodeficiency Virus-Infected Patients", Antimicrobiology Agents and Chemotherapy, 47 (1), pp. 238-243, January 2003.	
	40	Shrayer, et al., "Ceramide, a mediator of apoptosis, synergizes with paclitaxel to induce regression of the L 3.6 human pancreatic carcinoma implanted in SCDI mice", Journal of Clinical Oncology, Vol. 22, No. 14S, Abstract, 2004:2135.	
NA	41	Schroeder et al., "Distribution of Radiolabeled Subvisible Microspheres after Intravenous Administration to Beagle Dogs", Journal of Pharmaceutical Sciences, Vol. 67, No. 4, pp. 504-507, April 1978.	

Examiner Signature Date Considered 11-21-2005

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 08/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Apt of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number.

rute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet A of

Complete if Known				
Application Number	09/964,273			
Filing Date	September 26, 2001			
First Named Inventor	Sean Brynjelsen			
Art Unit	1615			
Examiner Name	P. A. Hawes			
Attorney Docket Number	CPIFT-5776 (3360-0004)			

NON PATENT LITERATURE DOCUMENTS					
Examiner Cit No					
014	42	Allen e al., "Large unilamellat liposomes with low uptake into the reticuloendothelial system", FEB, Vol. 223, No. 1, pp. 42-46, 1987.			
V	43	Allen et al., "Effects on the murine mononuclear phagocyte system of chronic administration of liposomes containing drug or lipid A compared with empty liposomes", Can. J. Physiol. Pharmacol., Vol. 65, pp. 185-190, 1987.			
	44	Graham, D.T., et al., "The Effects of Freezing on Commercial Insulin Suspensions", International Journal of Pharmaceutics, pp. 315-322, 1978.			
	45_	Bender et al., "Efficiency of Nanoparticles as a Carrier for Antiviral Agents in Human Immunodeficiency Virus-Infected Human Monocytes/Macrophases In Vitro", Antimicrobial Agents and Chemotherapy, 40(6), pp. 1467-1471, June 1996.			
	46	H. von Briesen, "Controled Release of Antiretroviral Drugs", AIDS Rev., 2, pp. 31-38, 2000.			
	47	Aquaro, et al., "Macrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir", Antiviral Research 55, pp. 209-225, 2002.			
		Crowe, et al., "The contribution of monocyte infection and trafficking to viral persistence, and maintenance of the viral reservoir in HIV infection", Journal of Leukocyte Biology, Vol. 74, pp. 635-641, November 2003.			
	49	Fischer-Smith et al., CNS invasion by CD14+/CD16+ peripheral blood-derived monocytes in HIV dementia: perivascular accumulation and reservoir of HIV infection", Journal of NeuroVirology, 7, pp. 528-541, 2001.			
AH .		Igarashi et al., "Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): Implications for HIV-1 infections of humans", PNAS, 98(2), pp. 658-663, January 16, 2001.			

Examiner Signature	halles-	Date Considered	11-21-2005

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS